Loading...
Birsa Agricultural University, Ranchi
Browse
2 results
Search Results
ThesisItem Open Access Pharmacokinetic Studies Of Levofloxacin In Healthy And Hepatopathic Turkeys(Birsa Agricultural University, Kanke, Ranchi, Jharkhand, 2010) Rupam, Richa; Roy, B. K. An overall view of result obtained indicated that LVX persisted for longer time in hepatopathic turkeys in case of both i.v. and oral administrations. Based on pharmacokinetic parameters LVX may be given i.v. @5.09 mg/kg body weight at 66.13h interval and orally @12.49mg/kg body weight at 88.16h interval in hepatopathic turkeys.ThesisItem Open Access Pharmacokinetic Studies Of Levofloxacin In Healthy And Hepatopathic Turkeys(Birsa Agricultural University, Kanke, Ranchi, Jharkhand, 2010) Rupam, Richa; Roy, B. K.The pharmacokinetic studies of levofloxacin (LVX) after intravenous (10 mg/kg body weight) and oral (20 mg/kg body weight) administration were conducted in healthy and hepatopathic turkeys. The silent features of the findings are given below: Intravenous administration: 1) The tCpther observed in hepatopathic turkeys (36 h) was longer than healthy (12 h). 2) The mean β value of LVX observed in hepatopathic turkeys (0.08±0.00 h–1) was significantly (p<0.01) lower as compared to healthy turkeys (0.26±0.01 h-1). 3) The mean t1/2β of LVX observed in hepatopathic turkeys (8.15±0.44 h) was significantly (p<0.01) longer as compared to healthy turkeys (2.68±0.14 h). 4) The mean AUC value of LVX in hepatopathic turkeys (50.63±6.70mg/L.h) was significantly (p<0.01) increased than healthy turkeys (21.39±1.99 mg/L.h). 5) The mean AUMC value of LVX in hepatopathic turkeys (570.32±156.53mg/L.h) was significantly (p<0.05) increased than healthy turkeys (80.80±11.40 mg/L.h). Pharmacokinetic studies of levofloxacin in healthy & hepatopathic turkeys 6) The MRT of LVX was significantly (p<0.01) longer in hepatopathic turkeys (12.38±0.78 h) to that observed in healthy turkeys (3.68±0.23 h). 7) The mean ClB value of LVX was found to be significantly (p<0.01) lower in hepatopathic turkeys (3.66±0.47 ml/kg/min) as compared to healthy turkeys (8.37±1.06 ml/kg/min). 8) The mean k21 value of LVX was found to be significantly (p<0.05) lower in hepatopathic turkeys (1.95±0.19 h–1) as compared to healthy turkeys (2.90±0.27 h–1). 9) The mean value of T/P ratio of LVX in hepatopathic turkeys (1.71±0.14) was significantly (p<0.05) higher as compared to healthy turkeys (1.16±0.15). Oral administration: 1) The mean Cpmax of LVX in hepatopathic turkeys (5.95±0.29 μg/ml) was non significantly increased as compared to healthy turkeys (5.34±0.26 μg/ml) and attained Tmax at 2 h in both cases. 2) The tCpther observed in healthy and hepatopathic turkeys were 24 h and 48 h respectively. Pharmacokinetic studies of levofloxacin in healthy & hepatopathic turkeys 3) The mean t1/2β of LVX was significantly (p<0.01) longer in hepatopathic turkeys (11.69±0.24 h) as compared to healthy (6.94±0.21 h). 4) The mean AUMC value of hepatopathic turkeys (957.85±64.20 mg/L.h) was significantly (p<0.01) higher than healthy turkeys (435.10±51.52 mg/L.h). 5) The MRT of LVX was found to be significantly (p<0.01) longer in hepatopathic turkeys (17.47±0.46 h) as compared to healthy turkeys (10.41±0.40 h). 6) The mean ClB value of LVX in hepatopathic turkeys (6.20±0.34 ml/kg/min) was significantly (p<0.01) decreased as compared to healthy turkeys (8.34±0.55 ml/kg/min). 7) The mean Vdarea of LVX in hepatopathic turkeys (6.28±0.38 L/kg) was significantly (p<0.05) increased as compared to healthy turkeys (4.97±0.27 L/kg). CONCLUSION An overallview of result obtained indicated that LVX persisted for longer time in hepatopathic turkeys in case of both i.v. and oral administrations. Based on pharmacokinetic parameters LVX may be given i.v. @5.09 mg/kg body weight at 66.13h interval and orally @12.49mg/kg body weight at 88.16h interval in hepatopathic turkeys.